Alternative titles; symbols
HGNC Approved Gene Symbol: TNFRSF8
Cytogenetic location: 1p36.22 Genomic coordinates (GRCh38): 1:12,063,303-12,144,207 (from NCBI)
In Hodgkin disease, the lymphoid activation antigen CD30 (Ki-1) is expressed on the tumor cells (Stein et al., 1982). Durkop et al. (1992) cloned the cDNA encoding the CD30 molecule.
By in vitro binding, immunoprecipitation, immunoblot, and yeast 2-hybrid analyses, Aizawa et al. (1997) showed that TRAF2 (601895) and TRAF5 (602356) interact with overlapping but distinct sequences in the C-terminal region of CD30 and mediate the activation of nuclear factor kappa-B (see 164011).
Several chronic inflammatory skin diseases are associated with increased numbers of mast cells and increased expression of CD30. Fischer et al. (2006) found that activation of mast cells in vitro with CD30 resulted in degranulation-independent secretion of the chemokines IL8 (146930), CCL3 (182283), and CCL4 (182284) in a MAP kinase-dependent manner. Mast cells were the predominant CD30L (603875)-positive cells in lesional skin from psoriasis and atopic dermatitis patients, and both CD30 and CD30L were upregulated in lesional skin in these conditions. The number of IL8-positive mast cells was also upregulated in psoriatic and atopic dermatitis lesional skin, and treatment of healthy skin organ cultures with CD30 resulted in IL8 expression. Fischer et al. (2006) concluded that CD30 mast cell activation represents an IgE-independent activation pathway important for understanding cutaneous inflammation associated with mast cells.
To gain insight into the mechanism of CD30 signaling in anaplastic large cell lymphoma and Hodgkin lymphoma, Wright and Duckett (2009) used an affinity purification strategy that led to the identification of the aryl hydrocarbon receptor nuclear translocator (ARNT; 126110) as a CD30-interacting protein that modulates the activity of the RelB subunit (604758) of the transcription factor nuclear factor kappa-B (NFKB; see 164011). Anaplastic large cell lymphoma cells that were deficient in ARNT exhibited defects in RelB recruitment to NFKB-responsive promoters, whereas RelA (164014) recruitment to the same sites was potentiated, resulting in the augmented expression of these NFKB-responsive genes. Wright and Duckett (2009) concluded that ARNT functions in concert with RelB in a CD30-induced negative feedback mechanism.
Fonatsch et al. (1992) demonstrated by in situ hybridization that the CD30 gene is located in the region 1p36. To increase the number of markers on distal mouse chromosome 4, McClive and Morahan (1994) used probes corresponding to loci on human 1p, known to have synteny homology to mouse chromosome 4, to reveal polymorphisms between C57BL/6 and DBA/2 mice, the progenitors of the 26 BXD recombinant inbred strains. Cd30 was tested with mouse-specific microsatellite markers and assigned to the genetic map of mouse chromosome 4.
Kurts et al. (1999) identified what they thought was a new mechanism that protects against autoimmunity mediated through CD30. In an erratum, they stated that the effects attributed to CD30 were the result of a background gene or genes of mouse strain 129 origin.
Aizawa, S., Nakano, H., Ishida, T., Horie, R., Nagai, M., Ito, K., Yagita, H., Okumura, K., Inoue, J., Watanabe, T. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-kappa-B activation. J. Biol. Chem. 272: 2042-2045, 1997. [PubMed: 8999898] [Full Text: https://doi.org/10.1074/jbc.272.4.2042]
Durkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B., Stein, H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68: 421-427, 1992. [PubMed: 1310894] [Full Text: https://doi.org/10.1016/0092-8674(92)90180-k]
Fischer, M., Harvima, I. T., Carvalho, R. F. S., Moller, C., Naukkarinen, A., Enblad, G., Nilsson, G. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J. Clin. Invest. 116: 2748-2756, 2006. [PubMed: 16964309] [Full Text: https://doi.org/10.1172/JCI24274]
Fonatsch, C., Latza, U., Durkop, H., Rieder, H., Stein, H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 14: 825-826, 1992. [PubMed: 1330892] [Full Text: https://doi.org/10.1016/s0888-7543(05)80203-4]
Kurts, C., Carbone, F. R., Krummel, M. F., Koch, K. M., Miller, J. F. A. P., Heath, W. R. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398: 341-344, 1999. Note: Erratum: Nature: 407: 413 only, 2000. [PubMed: 10192335] [Full Text: https://doi.org/10.1038/18692]
McClive, P. J., Morahan, G. Assignment of the mouse homologues of 6 loci from HSA1p to chromosomes 3 and 4. Genomics 23: 243-246, 1994. [PubMed: 7829080] [Full Text: https://doi.org/10.1006/geno.1994.1485]
Stein, H., Gerdes, J., Schwab, U., Lemke, H., Mason, D. Y., Ziegler, A., Schienle, W., Diehl, V. Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly detected small cell population. Int. J. Cancer 30: 445-449, 1982. [PubMed: 6754630] [Full Text: https://doi.org/10.1002/ijc.2910300411]
Wright, C. W., Duckett, C. S. The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappa-B-dependent transcription. Science 323: 251-255, 2009. [PubMed: 19131627] [Full Text: https://doi.org/10.1126/science.1162818]